Cargando…
VSV based virotherapy in ovarian cancer: the past, the present and …future?
The standard approach to treating patients with advanced epithelial ovarian cancer (EOC) after primary debulking surgery remains taxane and platinum-based chemotherapy. Despite treatment with this strategy, the vast majority of patients relapse and develop drug-resistant metastatic disease that may...
Autores principales: | Orzechowska, Beata Urszula, Jędryka, Marcin, Zwolińska, Katarzyna, Matkowski, Rafał |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5560156/ https://www.ncbi.nlm.nih.gov/pubmed/28819441 http://dx.doi.org/10.7150/jca.19473 |
Ejemplares similares
-
Oncolytic Virotherapy for Multiple Myeloma: Past, Present, and Future
por: Thirukkumaran, Chandini M., et al.
Publicado: (2011) -
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
por: Kottke, Timothy, et al.
Publicado: (2021) -
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma
por: Krabbe, Teresa, et al.
Publicado: (2021) -
Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
por: Cook, Joselle, et al.
Publicado: (2022) -
Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy
por: Marek, Janina, et al.
Publicado: (2023)